Fig. 5: Response rates and PFS of patients treated as per TuPro recommendations.
From: Feasibility of multiomics tumor profiling for guiding treatment of melanoma
a, Best response (CR, PR, SD, PD) in patients under palliative treatments (SOC and beyond SOC) in the Tumor Profiler cohort (TuPro, n = 82, 4 not evaluable). b, Best response (CR, PR, SD, PD) in patients under palliative at least third line treatment in the TuPro cohort (n = 37). c, Median PFS in months in patients receiving palliative treatments (SOC and beyond SOC) in the TuPro cohort (n = 86). d, Median PFS in months in patients receiving palliative at least third line treatment in the TuPro cohort (n = 37).
